@article{637e6044f6b94a6ebe634ba935552dce,
title = "Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD",
abstract = "na",
keywords = "Adult, Aged, Antineoplastic Agents, Hormonal, Autoantibodies, Benzamides, Chronic Disease, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Imatinib Mesylate, Lymphoproliferative Disorders, Male, Middle Aged, Monitoring, Physiologic, Myeloproliferative Disorders, Piperazines, Prednisolone, Prospective Studies, Protein Kinase Inhibitors, Pyrimidines, Receptors, Platelet-Derived Growth Factor, Severity of Illness Index, Survival Rate, Time Factors, Adult, Aged, Antineoplastic Agents, Hormonal, Autoantibodies, Benzamides, Chronic Disease, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Imatinib Mesylate, Lymphoproliferative Disorders, Male, Middle Aged, Monitoring, Physiologic, Myeloproliferative Disorders, Piperazines, Prednisolone, Prospective Studies, Protein Kinase Inhibitors, Pyrimidines, Receptors, Platelet-Derived Growth Factor, Severity of Illness Index, Survival Rate, Time Factors",
author = "Attilio Olivieri and Michele Cimminiello and Paolo Corradini and Nicola Mordini and Roberta Fedele and Carmine Selleri and Francesco Onida and Francesca Patriarca and Enzo Pavone and Silvia Svegliati and Armando Gabrielli and Paola Bresciani and Roberta Nuccorini and Sara Pascale and Pascale, {Sara Pasquina} and Sabrina Coluzzi and Fabrizio Pane and Antonella Poloni and Jacopo Olivieri and Pietro Leoni and Andrea Bacigalupo",
year = "2013",
doi = "10.1182/blood-2013-05-494278",
language = "English",
volume = "122",
pages = "4111--8--4118",
journal = "Blood",
issn = "0006-4971",
publisher = "[Philadelphia, Pa.] : W.B. Saunders Washington, DC : American Society of Hematology",
}